Mirae Asset Global Investments Co. Ltd. Sells 74,818 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Mirae Asset Global Investments Co. Ltd. lowered its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 85.5% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 12,721 shares of the company’s stock after selling 74,818 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Recursion Pharmaceuticals were worth $94,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. Allspring Global Investments Holdings LLC purchased a new position in shares of Recursion Pharmaceuticals during the third quarter valued at approximately $25,000. Decker Retirement Planning Inc. bought a new stake in Recursion Pharmaceuticals in the 4th quarter worth approximately $26,000. GAMMA Investing LLC raised its stake in Recursion Pharmaceuticals by 1,979.2% during the 4th quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock valued at $35,000 after buying an additional 4,948 shares during the last quarter. Farther Finance Advisors LLC boosted its stake in shares of Recursion Pharmaceuticals by 176.9% in the 3rd quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock worth $42,000 after buying an additional 4,091 shares during the last quarter. Finally, KBC Group NV grew its holdings in shares of Recursion Pharmaceuticals by 79.9% in the third quarter. KBC Group NV now owns 7,602 shares of the company’s stock worth $50,000 after acquiring an additional 3,377 shares during the period. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Price Performance

NASDAQ RXRX opened at $10.53 on Friday. The business’s fifty day moving average is $7.27 and its 200 day moving average is $6.92. Recursion Pharmaceuticals, Inc. has a fifty-two week low of $5.60 and a fifty-two week high of $15.74. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The company has a market capitalization of $4.11 billion, a PE ratio of -6.88 and a beta of 0.86.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the company. KeyCorp lowered their target price on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a report on Wednesday, January 8th. Needham & Company LLC reiterated a “buy” rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a research note on Thursday, February 6th.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.